New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 8, 2014
07:36 EDTAPRIApricus Biosciences announces multi-year partnership with SRF
Apricus Biosciences announced a multi-year partnership agreement with the Scleroderma Research Foundation, or SRF, to support the foundation's activities and the further progress of SRF's groundbreaking research programs. As part of the partnership, Apricus will co-sponsor an upcoming Scleroderma Research Roundtable Series and plans to participate in SRF's Annual Scientific Workshop and an SRF-sponsored event to take place at the upcoming American College of Rheumatology 2014 Annual Meeting. Apricus' product candidate for the treatment of Raynaud's phenomenon, RayVa, is expected to begin a phase 2a clinical trial in the second half of 2014.
News For APRI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 27, 2015
16:34 EDTAPRIApricus Biosciences announces issuance of U.S. patent for RayVa
Apricus Biosciences announced that , January 27, 2015, the United States Patent and Trademark Office, USPTO, issued to Apricus, U.S. Patent No. 8,940,794, titled "METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE," with claims generally directed to methods for treating Raynaud's phenomenon, that is secondary to systemic sclerosis. The patent is expected to expire no earlier than its twenty-year term in 2032. RayVa is the proprietary name for Apricus' product candidate for the treatment of Raynaud's phenomenon. Raynaud's phenomenon is a circulatory disorder affecting the hands and feet. Raynaud's phenomenon secondary to systemic sclerosis affects an estimated three to five percent of people in the U.S., disproportionately affecting women and currently has no approved therapy in the U.S., representing an unmet medical need. The FDA has indicated that Apricus' RayVa product may qualify for priority review, given the unmet medical need and lack of approved products to treat secondary Raynaud's phenomenon. The FDA will determine if the RayVa New Drug Application qualifies for priority review following its submission, which could occur as early as 2017.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use